“FDG PET/CT is most useful when there is clinical suspicion or other evidence for disease recurrence or metastases,” study coauthor Rathan M. Subramaniam, of the department of radiology at the University of Texas Southwestern Medical Center in Dallas, said in a statement, advising that “using FDG PET/CT for routine surveillance without any clinical suspicion should be discouraged until its value for patient survival outcomes is fully established.”  {read more here}

In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new positron emission tomography (PET) radiotracer, gallium-68 (Ga-68)-pentixafor, can quickly and non-invasively identify life-threatening atherosclerotic plaques. The tracer binds to the CXCR4 receptor on inflammatory cells present in atherosclerotic plaques—making it possible to find and treat atherosclerosis early. {read more here}

FDG positron emission tomography/computed tomography (PET/CT) is a valuable imaging tool for treatment assessment of patients with lung cancer, though systematic evidence for its comparative effectiveness with conventional imaging, such as chest CT, is still evolving, according to a new study. {read more here}

Researchers from the University of California, Davis (UC Davis) have revealed the first results from the EXPLORER project – which aims to build world’s first full total-body positron emission tomography (PET) scanner. {read more here}